Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage
This study has been completed.
First Received: September 13, 2005   Last Updated: January 15, 2007   History of Changes
Sponsor: ISTA Pharmaceuticals
Information provided by: ISTA Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00198497
  Purpose

The purpose of this study is to determine if intravitreal injection of Vitrase (ovine hyaluronidase) clears vitreous hemorrhage


Condition Intervention Phase
Vitreous Hemorrhage
Diabetic Retinopathy
Drug: Vitrase (ovine hyaluronidase)
Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment
Official Title: Phase III Safety and Efficacy Study of Vitrase (Ovine Hyaluronidase) for Ophthalmic Intravitreal Injection for Clearance of Severe Vitreous Hemorrhage

Resource links provided by NLM:


Further study details as provided by ISTA Pharmaceuticals:

Primary Outcome Measures:
  • Surrogate endpoint at 3-mo: laser treatment of underlying cause of vitreous hemorrhage, or other surgical treatment, or documented evidence of macula & at least 180 degrees of vitreous base, that vitreous hemorrhage cause is resolved

Secondary Outcome Measures:
  • Incidence of complication & adverse experience through 12 months; visual acuity for all subjects at 3, 6, 12 months

Estimated Enrollment: 556
Study Start Date: June 1999
Estimated Study Completion Date: June 2003
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Severe vitreous hemorrhage that obscures visualization of the fundus on indirect ophthalmoscopy, that has been present >/= 1 month by history or exam
  • BCVA is worse than 20/200 at time of screening

Exclusion Criteria:

  • Corneal or lenticular abnormalities that preclude fundus observation
  • Ongoing ocular infection, inflammation or history of herpetic corneal lesion
  • Current or prior retinal detachment or retinal tears or breaks or intraocular tumor
  • More than 1 severe vitreous hemorrhage within 6 months
  • Previous vitrectomy for any reason
  • Hemorrhage is exclusively pre-retinal, or old & organized
  • Prior Vitrase for intravitreal injection in either eye
  • No light perception in either eye at any time
  • Known contraindications to study medication
  • Sickle cell disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00198497

  Hide Study Locations
Locations
Australia, New South Wales
Royal North Shore Hospital
St. Leonards, New South Wales, Australia, 2088
University of Sydney
Sydney, New South Wales, Australia, 2000
University of Sydney/Westmead Hospital
Westmead, New South Wales, Australia, 2145
Australia, Queensland
Royal Brisbane Hospital
Herston, Queensland, Australia, 4029
Australia, South Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5000
Australia, Victoria
Royal Victorian Eye and Ear Hospital
East Melbourne, Victoria, Australia, 3002
Brazil, Goias
Universidade Federal de Goiania
Goiania, Goias, Brazil, 74210-010
Brazil, Minas Gerais
Universidade Federal de Minas Gerais
Belo Horizonte, Minas Gerais, Brazil, 30130-270
Brazil, PR
Universidade Federal do Parana
Curitiba, PR, Brazil, 80730-200
Brazil, RS
Universidade Federal do Rio Grande do Sul
Porto Alegre, RS, Brazil, 90035-003
Brazil, SP
Universidade de Sao Paulo
Sao Paulo, SP, Brazil, 01525-001
Universidade Federal de Sao Paulo, Escola Paulista e Medicina
Sao Paulo, SP, Brazil, 04023-062
Hungary
Medical University of Debrecen
Debrecen, Hungary, H4012
Central Army Hospital of the Hungarian Army
Budapest, Hungary, H1134
University of Szeged, Albert Szent-Gyorgyi Medical University
Szeged, Hungary, H6720
Medical University of Pecs
Pecs, Hungary, H7624
Uzsoki Street Hospital of the Municipality of Capital
Budapest, Hungary, H1145
Semmelweiss University
Budapest, Hungary, H1085
Italy
Universita degli Studi dell'Aguila
Coppito, Italy, I-67100
Universita degli Studi di Firenze
Firenze, Italy, I-50134
Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia
Roma, Italy, I-00161
Netherlands, AZ
University of Amsterdam
Amsterdam, AZ, Netherlands, 1105
Netherlands, GD
University Hospital Rotterdam
Rotterdam, GD, Netherlands, 3015
Netherlands, GZ
Academic Hospital Groningen
Groningen, GZ, Netherlands, 9713
Poland
Klinika Chorob Oczu
Bydgoszcz, Poland, 85-168
Medical Academy, Warsaw
Warsaw, Poland, 03-401
K. Marcinkowski University of Medical Sciences
Poznan, Poland, 61-841
Wroclaw University of Medicine
Wroclaw, Poland, 50-368
Medical Academy, Lodz
Lodz, Poland, 90-153
Main Regional Hospital
Poznan, Poland, 60-479
Silesian School of Medicine
Bytom, Poland, 41-902
Ophtalmology Clinic
Gdansk, Poland, 80-211
Ophthalmology Chair and Clinic
Lublin, Poland, 20-079
South Africa
Louis P. Kruger, MB, ChB
Johannesburg, South Africa, 2195
Groote Schuur Hospital
Cape Town, South Africa, 7937
Joseph J. Krouse, MB, ChB
Alberton, South Africa, 1449
James Acton, MB ChB
Bellville, South Africa, 7530
Kelvin N. Rivett, MB, ChB
East London, South Africa, 5201
Pretoria Eye Institute
Pretoria, South Africa, 0002
Nasionale Hospital
Bloemfontein, South Africa, 9301
Newlands Surgical Clinic
Cape Town, South Africa, 7708
South Africa, Durban
Addington Hospital
Congella, Durban, South Africa, 4001
Spain
Hospital de la Princesa
Madrid, Spain, 28006
Hospital Ramon y Cajal
Madrid, Spain, 28034
Hospital Universitario La Fe
Valencia, Spain, 46009
Instituto Oftalmologico de Alicante
Alicante, Spain, 03015
United Kingdom
Bristol Eye Hospital
Bristol, United Kingdom, BS1 2LX
Royal Liverpool University Hospital
Liverpool, United Kingdom, L7 8XP
Royal Victoria Infirmary
Newcastle Upon Tyne, United Kingdom, NE1 4LP
Oxford Eye Hospital
Oxford, United Kingdom, OX2 6HE
Kings College Hospital
London, United Kingdom, SE5 9RS
St. Thomas' Hospital
London, United Kingdom, SE1 7EH
Hull Royal Infirmary
Hull, United Kingdom, HU3 2JZ
United Kingdom, Denbighshire
H. M. Stanley Hospital
St. Asaph, Denbighshire, United Kingdom, LL17 0RS
United Kingdom, East Sussex
Sussex Eye Hospital
Brighton, East Sussex, United Kingdom, BN2 5BF
United Kingdom, Scotland
Aberdeen Royal Infirmary
Aberdeen, Scotland, United Kingdom, AB25 2ZN
Royal Infirmary of Edinburgh
Edinburgh, Scotland, United Kingdom, EH3 9HA
United Kingdom, Surrey
East Surrey Hospital
Redhill, Surrey, United Kingdom, RH1 5RH
Sponsors and Collaborators
ISTA Pharmaceuticals
Investigators
Study Director: Lisa R Grillone, PhD ISTA Pharmaceuticals, Inc.
  More Information

No publications provided by ISTA Pharmaceuticals

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):
Study ID Numbers: VIT-03-08961X
Study First Received: September 13, 2005
Last Updated: January 15, 2007
ClinicalTrials.gov Identifier: NCT00198497     History of Changes
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Eye Diseases
Vascular Diseases
Diabetes Mellitus
Endocrine System Diseases
Hemorrhage
Vitreous Hemorrhage
Diabetic Angiopathies
Diabetic Retinopathy
Pathologic Processes
Eye Hemorrhage
Cardiovascular Diseases
Retinal Diseases
Diabetes Complications

ClinicalTrials.gov processed this record on November 22, 2009